Lisinopril in Adults 65 and Older: Off-Label Uses, Dosing Adjustments, and Clinical Evidence

What Does "Off-Label" Mean for Lisinopril in Older Adults?

Off-label prescribing means a physician uses an FDA-approved drug for an indication, age group, dose, or route not listed on the manufacturer's label. Lisinopril's approved labeling does not specify distinct geriatric dosing protocols, nor does it list diabetic nephropathy, HFpEF, or migraine among its indications. Despite this, the American College of Cardiology, the American Diabetes Association, and major nephrology societies all recommend ACE inhibitors, including lisinopril, for several of these off-label scenarios in older patients.

Why "Off-Label" Does Not Mean "Unproven"

The FDA approval pathway requires evidence of safety and efficacy for the indication studied in clinical trials. A drug can accumulate decades of post-approval evidence supporting additional uses without those uses ever being formally re-submitted to the FDA. Lisinopril has been in clinical use since 1987, and large randomized controlled trials have examined its effects across multiple disease states in older populations. The absence of a label update reflects regulatory economics, not a lack of clinical data.

The Regulatory Field for ACE Inhibitors in Geriatric Patients

The FDA's geriatric labeling guidance requires prescribers to be aware that older adults often have reduced renal function, polypharmacy, and altered drug clearance. Lisinopril is eliminated almost entirely by the kidneys, so glomerular filtration rate drives dosing decisions far more than chronological age alone. The FDA's prescribing information for lisinopril notes that clinical studies "did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects," which is precisely why off-label evidence from dedicated geriatric substudies matters so much clinically. [1]

Off-Label Use 1: Diabetic Nephropathy in Older Adults

Lisinopril reduces intraglomerular pressure by blocking angiotensin II-mediated efferent arteriolar constriction. This mechanism slows the progression of diabetic kidney disease independent of its blood-pressure-lowering effect. Most landmark nephropathy trials enrolled mixed-age cohorts, but subgroup analyses confirm benefit extends into the 65-and-older population.

The EUCLID Trial and Renal Outcomes

The EUCLID trial examined lisinopril 10 to 20 mg daily in 530 normotensive patients with Type 1 diabetes and showed a 50% reduction in the rate of urinary albumin excretion increase over two years compared with placebo (P<0.05). [2] Although EUCLID primarily enrolled younger adults, its mechanistic findings apply directly to older patients with Type 1 or Type 2 diabetes who have microalbuminuria.

ADA Guidelines and Geriatric Considerations

The 2024 ADA Standards of Care state: "In patients with diabetes and hypertension, either an ACE inhibitor or an angiotensin receptor blocker is recommended for those with moderately or severely increased albuminuria to slow the progression of chronic kidney disease." [3] For patients 65 and older with an eGFR between 30 and 60 mL/min/1.73m², the starting dose is typically 2.5 to 5 mg once daily, titrated slowly to 10 to 20 mg as tolerated. Serum creatinine often rises 10 to 30% immediately after initiation; a rise <30% is acceptable and does not require drug discontinuation.

When to Avoid ACE Inhibitor Therapy in Older Diabetic Patients

Bilateral renal artery stenosis, a condition more prevalent in older adults with widespread atherosclerosis, is an absolute contraindication. Combining lisinopril with an ARB or direct renin inhibitor in this population is also contraindicated based on the ONTARGET trial (N=25,620), which showed dual blockade doubled the rate of acute kidney injury without additional cardiovascular benefit. [4]

Off-Label Use 2: Heart Failure with Preserved Ejection Fraction (HFpEF)

HFpEF accounts for roughly 50% of all heart failure cases and is far more prevalent in adults over 65 than in younger cohorts. Lisinopril is FDA-approved for heart failure with reduced ejection fraction (HFrEF, defined as EF <40%), but physicians commonly prescribe it in HFpEF, where EF is 50% or higher, to control blood pressure, reduce afterload, and address comorbid diabetes or CKD.

What the PEP-CHF Trial Showed

The PEP-CHF trial randomized 850 elderly patients (mean age 75.4 years) with diastolic heart failure to perindopril 4 mg or placebo. At one year, the perindopril group showed improvement in the 6-minute walk test and reduced hospitalization for heart failure (P<0.05). [5] Perindopril is a close pharmacological relative of lisinopril within the ACE inhibitor class, and cardiologists extrapolate these findings to lisinopril when selecting therapy for older HFpEF patients who also carry comorbid hypertension.

Current Guideline Position on ACE Inhibitors in HFpEF

The 2022 ACC/AHA/HFSA Heart Failure Guidelines give ACE inhibitors a Class IIb recommendation in HFpEF (EF >50%), acknowledging that evidence is less definitive than in HFrEF. The guidelines state: "ACE inhibitors or ARBs may be reasonable in patients with HFpEF to decrease hospitalizations." [6] In older adults, this recommendation is often operationalized through lisinopril because of its once-daily dosing and decades-long safety record.

Dosing Strategy in Older HFpEF Patients

Start at 2.5 mg once daily. Titrate by 2.5 to 5 mg increments every two to four weeks if systolic blood pressure remains above 110 mmHg and eGFR stays stable. Target doses of 10 to 20 mg daily are achievable in most patients whose renal function permits. Avoid rapid up-titration in frail older adults with borderline renal perfusion; symptomatic hypotension is more dangerous in this group because of reduced cerebral autoregulation and fall risk.

Off-Label Use 3: Migraine Prophylaxis

Migraine affects approximately 10% of adults over 65, and many first-line prophylactic agents, including tricyclic antidepressants and beta-blockers, carry disproportionate risks in older patients (anticholinergic burden, bradycardia, fatigue). Lisinopril has emerged as a lower-risk alternative.

The Norwegian Double-Blind Crossover Trial

A double-blind, crossover trial published in the BMJ (N=60, mean age 41 years) found that lisinopril 20 mg daily reduced the number of migraine days by 36% compared with placebo over 12 weeks (P=0.001). [7] Headache severity scores and days with migraine of at least moderate intensity also fell significantly. While the trial enrolled middle-aged patients, the mechanism, which involves reduction of angiotensin II-mediated cerebrovascular reactivity, is not age-dependent.

Practical Application in Adults 65 and Older

Neurologists and headache specialists prescribe lisinopril 10 to 20 mg daily as migraine prophylaxis in older adults who already carry comorbid hypertension or CKD, since the drug addresses both conditions simultaneously. The risk profile is favorable compared to topiramate (cognitive side effects, kidney stones) or valproate (hepatotoxicity, weight gain). No dedicated geriatric migraine prophylaxis trials with lisinopril have been published as of this writing.

A reasonable prescribing framework for this scenario: confirm the patient has at least four migraine days per month, rule out secondary headache causes, start lisinopril at 5 mg daily, and assess response after eight weeks before titrating to 20 mg. Check blood pressure and potassium at the four-week mark.

Off-Label Use 4: Scleroderma Renal Crisis Prevention

Systemic sclerosis (scleroderma) can trigger a hypertensive emergency with acute kidney injury known as scleroderma renal crisis, which occurs in 5 to 10% of patients with diffuse cutaneous disease. ACE inhibitors, including lisinopril, are the treatment of choice once crisis occurs. Some rheumatologists prescribe low-dose lisinopril prophylactically in high-risk older patients, particularly those receiving corticosteroids above 15 mg prednisone equivalent per day.

Evidence supporting prophylactic use remains observational. A retrospective analysis of 91 patients published in Arthritis and Rheumatism found that prior ACE inhibitor use was associated with milder renal crisis presentations and better short-term renal survival. [8] For older patients with scleroderma, the additional cardiovascular benefits of ACE inhibition add weight to a prophylactic strategy.

Pharmacokinetics and Renal Dosing in Adults 65 and Older

Lisinopril is not metabolized by the liver. It is absorbed in the gut, circulates without protein binding, and is cleared entirely through glomerular filtration and tubular secretion. This makes it one of the simplest ACE inhibitors to dose-adjust, because eGFR serves as a near-perfect proxy for drug clearance.

eGFR-Based Dose Adjustments

| eGFR (mL/min/1.73m²) | Starting Dose | Maximum Daily Dose | |---|---|---| | >60 | 5 to 10 mg | 40 mg | | 30 to 60 | 2.5 to 5 mg | 20 to 40 mg | | 10 to 30 | 2.5 mg | 10 mg | | <10 (dialysis) | 2.5 mg (post-dialysis) | 5 mg |

Data adapted from FDA prescribing information and KDIGO CKD guidelines. [1][9]

Why Older Adults Clear Lisinopril More Slowly

Average eGFR declines by roughly 0.7 to 1 mL/min/1.73m² per year after age 40. A 70-year-old patient with a serum creatinine of 1.1 mg/dL may have an eGFR of only 55 to 60 mL/min/1.73m², placing them in a reduced-dose category even though creatinine appears normal. The CKD-EPI equation, which accounts for age and sex, should be used to calculate eGFR before initiating lisinopril in any adult 65 or older. [9]

First-Dose Hypotension Risk

Older adults with activated renin-angiotensin systems, including those on diuretics, on low-sodium diets, or with decompensated heart failure, are at higher risk for first-dose hypotension. Blood pressure should be measured 1 to 2 hours after the first dose and again at the 24-hour mark if the patient is frail or has baseline systolic pressures below 130 mmHg.

Drug Interactions Particularly Relevant to Geriatric Patients

Polypharmacy is the norm in adults over 65. The average Medicare beneficiary takes more than five prescription drugs daily. Several drug classes interact with lisinopril in ways that amplify hyperkalemia or worsen renal function.

NSAIDs

Ibuprofen, naproxen, and celecoxib reduce prostaglandin-mediated efferent arteriolar dilation and can blunt lisinopril's antihypertensive effect while simultaneously increasing the risk of acute kidney injury. A pharmacoepidemiological study using UK primary care data found that combining ACE inhibitors with NSAIDs and diuretics (the "triple whammy" combination) was associated with a 31.2-fold increase in acute kidney injury hospitalization risk compared with neither drug. [10] Geriatric patients frequently use NSAIDs for arthritis pain; this interaction warrants explicit counseling.

Potassium-Sparing Diuretics and Potassium Supplements

Spironolactone, eplerenone, triamterene, and amiloride all raise serum potassium. Adding any of these to lisinopril in an older adult with even mild CKD should prompt potassium monitoring within one week. Trimethoprim, used commonly for urinary tract infections in older women, blocks tubular potassium secretion and has pharmacodynamic properties similar to amiloride; it should be considered a potassium-sparing agent in this context.

Aliskiren

The direct renin inhibitor aliskiren is contraindicated with lisinopril in patients with diabetes or eGFR <60, per the FDA label update following the ALTITUDE trial (N=8,606), which showed increased rates of non-fatal stroke, renal impairment, hyperkalemia, and hypotension with dual blockade. [11]

Monitoring Protocol for Older Adults on Lisinopril

Baseline Assessment

Before starting lisinopril, obtain: serum creatinine with calculated eGFR, serum potassium, urinalysis with albumin-to-creatinine ratio, and blood pressure in both arms. Document all concurrent medications.

Follow-Up Schedule

• 1 to 2 weeks post-initiation or dose change: repeat serum creatinine and potassium.
• 3 months after a stable dose is achieved: repeat the same labs.
• Every 6 to 12 months for stable patients on a consistent dose.

A rise in creatinine of more than 30% from baseline, or potassium above 5.5 mEq/L, should prompt dose reduction or temporary discontinuation and specialist consultation.

Cough Management

ACE inhibitor-induced cough occurs in 10 to 15% of patients, with higher rates in women and East Asian individuals. The cough results from bradykinin accumulation and does not respond to dose reduction. Switching to an angiotensin receptor blocker such as losartan or valsartan eliminates the cough while preserving the reno-protective and cardiovascular benefits in most off-label scenarios. [12]

Evidence from Major Cardiovascular Trials Relevant to the 65+ Population

ALLHAT Trial

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, N=33,357, mean age 66.9 years) compared lisinopril with chlorthalidone and amlodipine for primary prevention of fatal coronary heart disease and non-fatal MI. Lisinopril and chlorthalidone produced equivalent rates of the primary outcome. Black patients assigned to lisinopril had a 15% higher rate of stroke than those assigned to chlorthalidone, a finding that influenced subsequent guidelines favoring thiazides or calcium channel blockers as first-line therapy in Black older adults. [13]

HOPE Trial

The Heart Outcomes Prevention Evaluation trial (HOPE, N=9,297, mean age 66 years) tested ramipril, a closely related ACE inhibitor, versus placebo in patients at high cardiovascular risk. Over 4.5 years, ramipril reduced the composite of MI, stroke, and cardiovascular death by 22% (relative risk 0.78, 95% CI 0.70 to 0.86, P<0.001). [14] These data are widely used to support ACE inhibitor use, including lisinopril, in older adults with multiple cardiovascular risk factors even in the absence of heart failure.

Special Populations Within the Geriatric Cohort

Frail Older Adults

Frailty, defined by Fried criteria as three or more of the following: unintentional weight loss, exhaustion, low activity, slow gait speed, and weak grip, alters the risk-benefit calculation for any antihypertensive. In frail adults, aggressive blood pressure lowering is associated with worse outcomes. A 2019 systematic review in the BMJ found that antihypertensive therapy in adults over 80 with frailty increased fall-related hospitalizations without clear reductions in cardiovascular events. [15] Start at 2.5 mg daily, monitor blood pressure at home if possible, and set systolic targets at 130 to 150 mmHg rather than the 120 mmHg target used in SPRINT.

Adults Over 80

The HYVET trial (N=3,845, mean age 83.6 years) used indapamide with optional perindopril add-on in adults over 80 with systolic BP above 160 mmHg. Adding perindopril reduced stroke by 30% and heart failure by 64% (P<0.001) compared with placebo. [16] This supports ACE inhibitor use in octogenarians when the indication is clear and renal function is monitored, but dose ceilings remain lower than in younger patients.